SynAct Pharma announces additional data from the BEGIN study
SynAct Pharma AB (“SynAct”) today announced additional results on the secondary endpoints ACR50 and ACR70 from the Phase 2a study of AP1189 (BEGIN) in early rheumatoid arthritis (RA) patients experiencing severe disease activity.This update includes evaluation of the treatment effects by ACR scoring, named after the American College of Rheumatology. In addition to the ACR20 scores (proportion of the patients that achieved a reduction of ACR score ≥ 20%), the company has analyzed the treatment effects using the ACR50 and ACR70 scores. For ACR50 (≥50% improvement in the ACR score) the